RUNX2 and osteosarcoma: Moreover, combination therapy effectively downregulated the RUNX2/pAKT signaling pathway, which is implicated in osteosarcoma progression and drug resistance, thereby enhancing the pro-apoptotic effects of doxo while mitigating its limitations.